- Expert panel to present on next generation T-Cell therapy using the natural killer cell receptor NKG2D
- Celyad to present its immune-oncology portfolio with emphasis on the natural killer receptor T-Cell (NKR T-Cell) program and its exciting pre-clinical data
- Update from Celyad on clinical progress and future development plans
MONT-SAINT-GUIBERT, Belgium, Feb. 29, 2016 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, today announced that it will host an Immuno-Oncology R&D Analyst Day on Thursday, March 24th from 8:00am - 11am Eastern Time in New York City.
The meeting is intended for institutional investors and sell-side analysts. It will feature several members of the Celyad management team as well as a panel of experts including;
- Jeffrey S. Weber, MD, PhD, Deputy Director of the Laura & Isaac Perlmutter Cancer Center, Co-Director, Melanoma Program, and Professor of Medicine at NY Langone Medical Center;
- Julie Y. Djeu, PhD, Associate Center Director for Education & Training, Senior Member, Immunology Program, and the Garcia Endowed Chair in Cancer Leadership at the Moffitt Cancer Center;
- Charles Sentman, PhD, Director, Center for Synthetic Immunity, and Professor, Department of Microbiology & Immunology at the Geisel School of Medicine at Dartmouth;
- Sarah Nikiforow, MD, PhD, Assistant Medical Director, Clinical Instructor, Stem Cell Transplantation Program, Cell Manipulation Core Facility at the Dana-Farber Cancer Institute, and Instructor in Medicine at Harvard Medical School.
Patrick Jeanmart, Chief Financial Officer at Celyad: “This R&D Day will be a great opportunity for us to share the latest updates on our natural killer receptor T-Cells (NKR T-Cell) and also to explain, thanks to the support of keynote scientific experts, the whole potential of our platform in immuno-oncology”.
A live webcast of the event will be available at http://lifesci.rampard.com/20160324. It will also be available, post-event, in the Events section of the Company’s website at www.celyad.com.
For more information, please contact Andrew MacDonald at 212-915-2567 or via e-mail at mac@lifesciadvisors.com
To subscribe to Celyad’s newsletter, visit www.celyad.com
Follow us on Twitter @CelyadSA
About NKR-2
Celyad’s lead immuno-oncology product candidate, NKR-2, is a T-Cell encoded to express the Natural Killer activating receptor, NKG2D. The technology developed by Celyad uses a human natural killer cell (NK cell) receptor which, unlike traditional CAR technologies, targeting the CD19 antigen, has the potential to target ligands expressed on a broad range of solid tumors and blood cancers.
The research underlying this technology was originally conducted by Dartmouth College Professor Charles Sentman, and has been published in numerous peer-reviewed publications such as Journal of Immunology in 2009, Cancer Research in 2006, and Blood in 2005. NKR-2 has an active Investigational New Drug (IND) application with the FDA for a Phase I clinical trial in certain hematologic cancers.
NKR-2 entered a Phase I clinical trial in April 2015. The full data readout from the Phase I dose escalation trial is expected in mid-2016. The trial is designed to assess the safety and feasibility of NKR-2 in acute myeloid leukemia and multiple myeloma patients, with secondary endpoints including clinical efficacy.
About Celyad
Founded in 2007, and based in Belgium, Celyad is a leader in engineered cell therapy with clinical programs initially targeting indications in cardiology and oncology. Celyad is developing its lead cardiovascular disease product candidate, C-Cure®, for the treatment of ischemic heart failure, and has completed enrollment of a Phase III trial in Europe and Israel. In addition, the Company is developing a next generation portfolio of CAR T-cell therapies that utilize human Natural Killer cell receptors for the treatment of numerous blood and solid cancers. Its lead oncology product candidate, NKR-2 (NKG2D CAR T-cell), entered a Phase I clinical trial in April 2015.
Celyad’s ordinary shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CYAD and Celyad’s American Depositary Shares are listed on the NASDAQ Global Market under the ticker symbol CYAD.
To learn more about Celyad, please visit www.celyad.com
Forward looking statements
In addition to historical facts or statements of current condition, this press release contains forward-looking statements, including statements about the potential safety and feasibility of NKR-2-cell therapy and C-Cure and the clinical potential of the Company’s technology platform generally and the timing of future clinical trials, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements.
In particular it should be noted that the safety data described in the release are preliminary in nature and the Phase 1 trial is not completed. There is limited data concerning safety and feasibility of NKR-2. These data may not continue for these subjects or be repeated or observed in ongoing or future studies involving our NKR-2 therapy, C-Cure or other product candidates. It is possible that safety issues or adverse events may arise in the future.
These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including risks associated with conducting clinical trials; the risk that safety, bioactivity, feasibility and/or efficacy demonstrated in earlier clinical or pre-clinical studies may not be replicated in subsequent studies; risk associated with the timely submission and approval of anticipated regulatory filings; the successful initiation and completion of clinical trials, including Phase III clinical trials for C-Cure® and Phase I clinical trial for NKR-2; risks associated with the satisfaction of regulatory and other requirements; risks associated with the actions of regulatory bodies and other governmental authorities; risks associated with obtaining, maintaining and protecting intellectual property, our ability to enforce our patents against infringers and defend our patent portfolio against challenges from third parties; risks associated with competition from others developing products for similar uses; risks associated with our ability to manage operating expenses;, and risks associated with our ability to obtain additional funding to support our business activities and establish and maintain strategic business alliances and business initiatives. A further list and description of these risks, uncertainties and other risks can be found in the Company’s Securities and Exchange Commission filings and reports, including in the Company’s prospectus filed with the SEC on June 19, 2015 and future filings and reports by the Company. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. The Company expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.
C3BS-CQR-1, C-Cure, NKG2D CAR T-cell, NKR-2, C-Cathez TM, OnCyte, Celyad, Celyad, C-CathezTM, CHART-1, CHART-2 and OnCyte logos are signs internationally protected under applicable Intellectual Property Laws. Mayo Clinic holds equity in Celyad as a result of intellectual property licensed to the Company.